Curis Approves Key Amendments at Annual Meeting

Curis ( (CRIS) ) has shared an update.

On May 20, 2025, Curis, Inc. held its Annual Meeting of Stockholders virtually, where several key amendments were approved. The stockholders approved an amendment to the company’s stock incentive plan to reserve an additional 1,255,000 shares of common stock, increasing the total authorized shares for issuance. Additionally, an amendment to the company’s Restated Certificate of Incorporation was adopted, increasing the number of authorized shares of capital stock and common stock significantly. The board also approved changes to the company’s bylaws, reducing the quorum requirement for stockholder meetings. These changes aim to enhance the company’s operational flexibility and shareholder engagement.

The most recent analyst rating on (CRIS) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.

Spark’s Take on CRIS Stock

According to Spark, TipRanks’ AI Analyst, CRIS is a Neutral.

Curis’ overall stock score is primarily impacted by its weak financial performance and valuation. While there are promising clinical developments, the negative financial metrics and need for additional funding pose significant risks. The earnings call provided some optimism, but financial instability remains the most pressing concern.

To see Spark’s full report on CRIS stock, click here.

More about Curis

Average Trading Volume: 79,979

Technical Sentiment Signal: Strong Sell

Current Market Cap: $22.18M

For a thorough assessment of CRIS stock, go to TipRanks’ Stock Analysis page.